Ten days ago I wrote that the dynamics highlighted by this year’s Catalyst Pharma Fast 50 show the sector is prime for further acquisitions and private equity investment.
Today Quotient Clinical, one of the companies which features in the Pharma Fast 50, announced it has acquired US-based SeaView Research for its complementary customer portfolio and to provide a broader set of services to Quotient's existing client base. This also establishes an operational footprint in the US for Quotient.
This is one of the first mid-market pharma acquisitions of the year involving UK companies; however, there is certainly more to come.
A profile on Quotient Clinical can be found in our full report:
http://www.catalystcf.co.uk/research-documents/2016/catalyst-pharma-fast-50_1.pdf
Quotient Clinical (“Quotient”), the early phase drug development services provider, today announces that it has acquired SeaView Research (“SeaView”), expanding its operations into the USA. The acquisition combines Quotient and SeaView’s complementary customer portfolios, and strengthens the early phase clinical experience of the combined business, enabling the company to deliver a broader set of services.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=204317#.WJhoQOSmknU
